

1,3,5-TRIAZA-7-PHOSPHAADAMANTANE

Page: 1 Compilation date: 13/05/2015 Revision date: SAP Revision No: 1

#### Section 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1. Product identifier

Product name: 1,3,5-TRIAZA-7-PHOSPHAADAMANTANE

CAS number: 53597-69-6

Product code: OR460058

Synonyms: PTA

### 1,3,5-TRIAZA-7-PHOSPHATRICYCLO[3.3.1.1{3,7}]DECANE

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against

#### **1.3. Details of the supplier of the safety data sheet**

Company name: Apollo Scientific Ltd Units 3 & 4 Parkway Denton Manchester M34 3SG UK

> **Tel:** 0161 337 9971 **Fax:** 0161 336 6932

Email: david.tideswell@apolloscientific.co.uk

### 1.4. Emergency telephone number

#### Section 2: Hazards identification

#### 2.1. Classification of the substance or mixture

Classification under CLP: This product has no classification under CLP.

#### 2.2. Label elements

Label elements:	
Precautionary statements:	P271: Use only outdoors or in a well-ventilated area.
	P261: Avoid breathing dust.
	P280: Wear protective gloves/protective clothing/eye protection/face protection.
2.3. Other hazards	
Other hazards:	Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.

This substance is not classified as dangerous according to Directive 67/548/EEC.

**PBT:** This product is not identified as a PBT/vPvB substance.

# 1,3,5-TRIAZA-7-PHOSPHAADAMANTANE

		Page:	2	
Section 3: Composition/information	ation on ingredients			
3.1. Substances				
Chemical identity:	1,3,5-TRIAZA-7-PHOSPHAADAMANTANE			
CAS number:				
Section 4: First aid measures				
4.4. Decemination of first aid more				
4.1. Description of first aid mea	sures			
Skin contact:	Wash immediately with plenty of soap and water.			
Eye contact:	Bathe the eye with running water for 15 minutes.			
Ingestion:	Wash out mouth with water.			
Inhalation:	Consult a doctor.			
4.2. Most important symptoms a	and effects, both acute and delayed			
Skin contact:	There may be mild irritation at the site of contact.			
Eye contact:	There may be irritation and redness.			
Ingestion:	There may be irritation of the throat.			
Inhalation:	There may be irritation of the throat with a feeling of tightness in the chest.			
4.3. Indication of any immediate	medical attention and special treatment needed			
Immediate / special treatment:	Not applicable.			
Section 5: Fire-fighting measur	es			
5.1. Extinguishing media				
Extinguishing media:	Suitable extinguishing media for the surrounding fire should be used. Use water spray			
	to cool containers.			
5.2. Special hazards arising from	n the substance or mixture			
Exposure nazaros.	In combustion emits toxic fumes of carbon dioxide / carbon monoxide. Nitrogen oxides			
	(NOx). Oxides of phosphorus.			
5.3. Advice for fire-fighters				
Advice for fire-fighters:	Wear self-contained breathing apparatus. Wear protective clothing to prevent contact			
	with skin and eyes.			
Section 6: Accidental release m	easures			
6.1. Personal precautions, prote	ective equipment and emergency procedures			
Personal precautions:	Refer to section 8 of SDS for personal protection details. Do not create dust.			
6.2. Environmental precautions				
Environmental precautions:	Do not discharge into drains or rivers. Contain the spillage using bunding.		-	

## 1,3,5-TRIAZA-7-PHOSPHAADAMANTANE

		<b>Page:</b> 3
6.3. Methods and material for co	ontainment and cleaning up	
Clean-up procedures:	Wash the spillage site with large amounts of water. Transfer to a closable, labelled	
	salvage container for disposal by an appropriate method.	
6.4. Reference to other sections		
Reference to other sections:		
Section 7: Handling and storage	e	
7.1. Precautions for safe handling	ng	
Handling requirements:	Ensure there is sufficient ventilation of the area. Avoid the formation or spread of dust in	
	the air. Keep container tightly closed. Close container after use or when empty. Only use	
	in fume hood.	
7.2 Conditions for safe storage	, including any incompatibilities	
Storage conditions:	Store in a cool, well ventilated area. Keep container tightly closed. Product is	
	hygroscopic. Take precautions to avoid contact with atmospheric moisture. Store under	
	Argon.	
7.3. Specific end use(s)		
Specific end use(s):	No data available.	
Section 8: Exposure controls/p	ersonal protection	
8.1. Control parameters		
Workplace exposure limits:	No data available.	
DNEL/PNEC Values		
DNEL / PNEC	No data available.	
8.2. Exposure controls		
Engineering measures:	Ensure there is sufficient ventilation of the area.	
	Respiratory protection not required.	
	Protective gloves.	
-	Safety glasses. Ensure eye bath is to hand.	
	Protective clothing.	
Section 9: Physical and chemic	ai properties	

# 9.1. Information on basic physical and chemical properties

State: Solid Colour: White

Melting point/range °C: 244-250

#### 1,3,5-TRIAZA-7-PHOSPHAADAMANTANE

Page: 4

#### 9.2. Other information

Other information: No data available.

#### Section 10: Stability and reactivity

#### 10.1. Reactivity

Reactivity: Stable under recommended transport or storage conditions.

#### 10.2. Chemical stability

Chemical stability: Stable under normal conditions.

#### 10.3. Possibility of hazardous reactions

Hazardous reactions: Hazardous reactions will not occur under normal transport or storage conditions.

Decomposition may occur on exposure to conditions or materials listed below.

## 10.4. Conditions to avoid

Conditions to avoid: Heat.

10.5. Incompatible materials

Materials to avoid: Strong oxidising agents. Strong acids.

#### 10.6. Hazardous decomposition products

Haz. decomp. products: In combustion emits toxic fumes of carbon dioxide / carbon monoxide. Nitrogen oxides

(NOx). Oxides of phosphorus.

## Section 11: Toxicological information

#### 11.1. Information on toxicological effects

Toxicity values: No data available.

Symptoms / routes of exposure

Skin contact: There may be mild irritation at the site of contact.

Eye contact: There may be irritation and redness.

**Ingestion:** There may be irritation of the throat.

Inhalation: There may be irritation of the throat with a feeling of tightness in the chest.

## Section 12: Ecological information

12.1. Toxicity

Ecotoxicity values: No data available.

12.2. Persistence and degradability

Persistence and degradability: No data available.

12.3. Bioaccumulative potential

Bioaccumulative potential: No data available.

# 1,3,5-TRIAZA-7-PHOSPHAADAMANTANE

		Page:
12.4. Mobility in soil		
Mobility:	No data available.	
12.5. Results of PBT and vPvB		
	This product is not identified as a PBT/vPvB substance.	
12.6. Other adverse effects		
Other adverse effects:	No data available.	
Section 13: Disposal considera	tions	
13.1. Waste treatment methods		
Disposal operations:	MATERIAL SHOULD BE DISPOSED OF IN ACCORDANCE WITH LOCAL, STATE AND	
	FEDERAL REGULATIONS	
Disposal of packaging:	Dispose of as special waste in compliance with local and national regulations Observe	
	all federal, state and local environmental regulations.	
NB:	The user's attention is drawn to the possible existence of regional or national	
	regulations regarding disposal.	
Section 14: Transport information	on	
Transport class:	This product does not require a classification for transport.	
Section 15: Regulatory informa	tion	
15.1. Safety, health and environ	mental regulations/legislation specific for the substance or mixture	
15.2. Chemical Safety Assessm	ent	
Chemical safety assessment:	A chemical safety assessment has not been carried out for the substance or the mixture	
	by the supplier.	
Section 16: Other information		
Other information		
Other information:	This safety data sheet is prepared in accordance with Commission Regulation (EU) No	
	453/2010.	
	* Data predicted using computational software. Toxtree - Toxic Hazard Estimation by	
	decision tree approach. http://ecb.jrc.ec.europa.eu/qsar/qsar-tools/index.php?	
	c=TOXTREE	
	~ Data predicted using computational software ACD/ToxSuite v 2.95.1 Copyright 1994-	
	2009 ACD/labs, Copyright 2001-2009 Pharma Algorithms, Inc, Advanced Chemistry	
	Development, Inc (ACD/Labs). http://www.acdlabs.com/products/pc_admet/tox/tox/	
Legend to abbreviations:	PNEC = predicted no effect level	
	DNEL = derived no effect level	
	LD50 = median lethal dose	
		<b>.</b> .
		[cont.

#### 1,3,5-TRIAZA-7-PHOSPHAADAMANTANE

LC50 = median lethal concentration EC50 = median effective concentration IC50 = median inhibitory concentration dw = dry weight bw = body weight cc = closed cup oc = open cup MUS = mouse GPG = guinea pig RBT = rabbit HAM = hamster HMN = human MAM = mammal PGN = pigeon IVN = intravenous SCU = subcutaneous

SKN = skin

DRM = dermal

OCC = ocular/corneal

PCP = phycico-chemical properties

Legal disclaimer: The material is intended for research purposes only and should be handled exclusively by those who have been fully trained in safety, laboratory and chemical handling procedures. The above information is believed to be correct to the best of our knowledge. The above information is believed to be correct to the best of our knowledge at the date of its publication, but should not be considered to be all inclusive. It should be used only as a guide for safe handling, storage, transportation and disposal. We cannot guarantee that the hazards detailed in this document are the only hazards that exist for this product. This is not a warranty and Apollo Scientific Ltd shall not be held liable for any damage resulting from handling or from contact with the above product.

Page: 6